Home » Posts tagged with » Drug discovery
PostEra, Pfizer partner to advance machine learning for drug discovery

PostEra, Pfizer partner to advance machine learning for drug discovery

PostEra, a biotech company specializing in machine learning solutions for preclinical drug discovery, has forged a partnership with Pfizer for speeding up the discovery of small molecule drugs by using a platform technology based on generative chemistry. The company’s machine learning technology can fast track the drug discovery process by designing novel molecular structures that […]

PharmaEngine, Sentinel Oncology partner to advance SOL-578 Chk1 inhibitor

PharmaEngine has signed a collaboration and license deal with UK-based Sentinel Oncology for advancing the new drug development of SOL-578, a checkpoint kinase 1 inhibitor (Chk1 inhibitor). As per the agreement, the Taiwanese pharma company will finance the investigational new drug (IND) enabling studies for SOL-578. Sentinel Oncology is a drug discovery company engaged in […]

Continue reading …
PerkinElmer to acquire cell engineering company Horizon Discovery

US-based PerkinElmer will acquire UK-based cell engineering company Horizon Discovery Group for nearly $383 million in an all-cash deal. The transaction, which is subject to the meeting of customary closing conditions, expected to be completed in Q1 2021. Through the deal, PerkinElmer will expand its portfolio of automated life sciences discovery and applied genomics solutions […]

Continue reading …
Ligand Pharmaceuticals to acquire protein therapeutics developer Pfenex

US biopharma company Ligand Pharmaceuticals has signed a deal worth up to $516 million to acquire Pfenex, a development and licensing biotechnology company engaged in the development of protein therapeutics, which are used in various commercial and development-stage biopharma drug candidates. As per the terms of the deal, Ligand Pharmaceuticals is offering to acquire the […]

Continue reading …
Curi Bio acquires Dana Solutions to boost drug discovery platforms

Curi Bio, a developer of human iPSC-based platforms for drug discovery, has acquired Dana Solutions, a provider of artificial intelligence and machine learning technologies for in vitro cell-based assays. Financial terms of the deal were not disclosed by the parties. Curi Bio, through the acquisition, will get access to Dana Solutions’ artificial intelligence and machine […]

Continue reading …
Cyclica, Genome Institute of Singapore sign drug discovery partnership

Canadian biotech company Cyclica has signed a multi-year and multi-project drug discovery partnership with the Genome Institute of Singapore (GIS) in oncology and related diseases. The partners will undertake research efforts, which will span from polypharmacology profiling to novel compound design for diverse drug discovery programs. The collaboration will utilize the deep expertise of Genome […]

Continue reading …
Gilead Sciences, Second Genome form IBD drug discovery alliance

Gilead Sciences has entered into a four-year deal worth up to $338 million with California-based clinical-stage company Second Genome to discover targets and drug candidates for the treatment of inflammatory bowel disease (IBD). The companies will also collaborate on detecting biomarkers related to clinical response for a maximum of five pipeline compounds of Gilead Sciences, […]

Continue reading …
Polarisqb, Fujitsu join forces to create dengue drug discovery platform

Polarisqb has joined forces with Fujitsu to create a Dengue drug discovery platform that brings together quantum-inspired technology, hybrid quantum mechanics, machine learning, and molecular mechanics simulations (QM/MM). The new platform is expected to help in significantly quicker, more cost-effective discovery of novel lead molecules for developing new drugs. Polarisqb and Fujitsu have started a […]

Continue reading …
AbbVie, Scripps Research to collaborate on developing new therapeutics

US biopharma company AbbVie has entered into a collaboration with California-based nonprofit medical research facility Scripps Research with a goal to develop new therapies for a variety of diseases, including in the therapeutic areas of oncology, immunology, fibrosis, and neurology. Peter Schultz – CEO of Scripps Research and Calibr, its drug discovery unit, said: “Based […]

Continue reading …
GE Healthcare, ASLS form R&D partnership to advance 3D biofabrication

GE Healthcare Life Sciences has joined forces with Advanced Solutions Life Sciences (ASLS) for an R&D and distribution partnership with a goal to create new opportunities for regenerative tissue manufacturing by advancing the field of 3D biofabrication. The companies said that the integration of IN Cell Analyzer and BioAssemblyBot systems technologies will embed cellular-level evaluations […]

Continue reading …
Page 1 of 212